Introduction
Neovascularization in the retina is a key pathology in several ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). It is a primary cause of severe vision loss. The most advanced anti-angiogenic treatments, including anti-VEGF therapy, are effective, but only improve vision significantly in 25-40% patients (Hernandez-Pastor, Ortega, Garcia-Layana, & Giraldez, 2008; Rosenfeld, Rich, & Lalwani, 2006) . While VEGF is a dominant factor in pathological neovascularization, retinal neovascularization has a complex etiology, possibly including multiple genetic and nongenetic factors. These factors include expression and/or activities of complement, integrin, platelet-derived growth factor, inflammatory cytokines, oxidants, and macrophages, which play important roles in various stages of retinal neovascularization (Klein, 2007) . Clinical management of retinal neovascularization remains a great challenge, and novel treatment strategies that target multiple components of the angiogenesis cascade hold great potential to improve clinical outcomes.
APE1/Ref-1 (also known as Ref-1, HAP1, hAPE, APE or APEX) is a multi-functional protein with apurinic/apyrimidinic endonuclease activity, encoded by an evolutionarily conserved C-terminal domain, and reduction-oxidation (redox) activity, encoded by a functionally-independent N-terminal domain unique to mammalian members of this protein family (Tell, Damante, Caldwell, & Kelley, 2005; Xanthoudakis, Miao, & Curran, 1994) . APE1/Ref-1 redox activity stimulates numerous transcription factors that are involved in cancer promotion and progression, such as PAX, HIF1a and NFjB, AP-1 (Fos/Jun), HLF, p53, and others (Evans, LimpFoster, & Kelley, 2000; Fishel & Kelley, 2007; Tell et al., 2005) . Several of these transcription factors also play roles in angiogenesis (i.e., HIF-1a (Carmeliet et al., 1998; Gariano & Gardner, 2005) , NFjB (Huang, Pettaway, Uehara, Bucana, & Fidler, 2001; Huang, Robinson, Deguzman, Bucana, & Fidler, 2000; Yoshida, Yoshida, Ishibashi, Kuwano, & Inomata, 1999) , and AP-1 (Tischer et al., 1991) ; for review see Maulik (2002) . In addition, a high level of APE1/Ref-1 expression is associated with more active angiogenesis and chemotherapy resistance in tumors (Bicknell & Harris, 2004; Bilton & Booker, 2003) . Selective inhibition of the APE1/Ref-1 redox function by APX3330 (E3330/BQP) inhibits the growth of tumor endothelium and endothelial progenitor cells (Zou et al., 2008) . Our recent report that APX3330 significantly attenuates proliferation and tube formation of retinal vascular endothelial cells (RVECs) suggests that APE1/Ref-1 could play a role in retinal angiogenesis (Luo et al., 2008) .
This study explores the role of the APE1/Ref-1 redox function during retinal angiogenesis in vitro in RVEC cells and in vivo in Vldlr À/À mice. The Vldlr À/À mouse develops spontaneous age-related RAP-like neovascularization evolving from the retina which mimics the essential histological and angiographic characteristics of retinal angiomatous proliferation (RAP), a subtype of neovascular AMD (Heckenlively et al., 2003; Hu et al., 2008; Li et al., 2007) . The results show that APX3330 potently inhibits the growth of RVEC in vitro and significantly reduces RAP-like neovascularization in Vldlr 
Materials and methods

Experimental animals
All animals used in the study were maintained and treated with strict adherence to the guidelines for animal care and experimentation prepared by the Association for Research in Vision and Ophthalmology and approved by the Henry Ford Health System Animal Care and Use Committee. Breeding pairs of mutant mice with targeted deletion of the Vldlr gene (B6; 129S7-Vldlr tm1Her /J; Vldlr À/À ) (Frykman, Brown, Yamamoto, Goldstein, & Herz, 1995) were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). Breeding pairs of an ImmortoMouse Ò transgenic line expressing a temperature-sensitive SV40 large T antigen were obtained from the Charles River Laboratories (Wilmington, MA). Both wild-type (C57BL/6J; +/+) and Vldlr À/À mice were crossbred with the transgenic ImmortoMouse, respectively. Cells isolated from the littermates produced from these crosses can be immortalized by turning on the SV40 gene in vitro. All offspring were subjects for PCR genotype confirmation of SV40, wild-type Vldlr, and Vldlr knockout genes.
Matrigel tube formation assay
Early passage (2-4 days) of human umbilical cord blood-derived endothelial colony forming cells (ECFCs) were starved in EBM2 (Lonza, Walkersville, MD) + 0.5% FBS (Hyclone, Logan, UT) for 16 h. ECFCs were detached with trypsin EDTA (Invitrogen, Carlsbad, CA) and a viable cell count obtained via trypan blue exclusion. Cells were suspended in EBM2 + 0.5% FBS with vehicle only or varying concentrations of APX3330 dissolved in DMSO or Avastin Ò (Genentech, San Francisco, CA). DMSO/vehicle controls were routinely included in the assay. Seven thousand five hundred cells per well were plated into 96 well tissue culture plates pre-coated with matrigel. Each condition was plated in triplicate. Plates were incubated at 37°C in a 5% CO 2 , humidified incubator and examined after 6-8 h for tube formation. Low magnification images were captured to quantify the total number of closed network units formed per well. The same assay was also performed in RVECs isolated from wild-type and Vldlr À/À mice (Nagata, Mogi, & Walsh, 2003) .
TUNEL assay
TdT mediated dUTP-fluorescein nick end-labeling (TUNEL) assay which allows us to determine the percentage of cells undergoing apoptosis. The reactions were performed following the manufacture's protocol (Roche, Indianapolis, IN). Cells were treated with various concentrations of APX3330 for 24 h. A 100 lM H 2 O 2 group was included to serve as a positive control.
Random fields of cells are photographed under phase microscopy and scored as percent positive cells for the terminal transferase labeling reaction.
RVEC primary culture
Mouse RVECs and retinal pericytes (RPCs) were isolated as described before with modifications (Su, Sorenson, & Sheibani, 2003) . Briefly, retinal tissues from young adult wild-type and Vldlr À/À mice carrying a SV40 transgene were digested with collagenase type I (Worthington, Lakewood, NJ) in DMEM. The dissociated cells were incubated with sheep anti-rat magnetic beads (Dynal Biotech, Lake Success, NY) pre-coated with a rat anti-mouse PECAM-1 monoclonal antibody (BD Biosciences, San Jose, CA) for affinity binding of RVECs. Bead-bound cells were seeded in a 24-well plate pre-coated with fibronectin (BD Biosciences, San Jose, CA) in an endothelial cell growth medium (EBM/EGM-2MV, Cambrex). Detailed characterization of these cells (>95% endothelial cells) are described in our recent publication (Jiang, Hu, Meng, Gao, & Qiao, 2009) . A similar protocol was used to isolate retinal pericyte but using anti-mouse a-SMA antibody to label the magnetic beads, Cells were maintained in culture at 33°C with interferon to turn on the SV40 gene, but were assayed under ordinary conditions at 37°C in the absence of interferon.
Western blot
Whole cell/tissue extract were prepared using RIPA buffer supplemented with protease inhibitor cocktail. The protein extract were separated by 10% SDS-PAGE electrophoresis, and transferred to a nitrocellulose membrane. After blocking in 5% non-fat milk in TBS/T buffer, blots were probed with an anti-APE1/Ref-1 monoclonal antibody (Novus Biologicals) and an anti-tubulin monoclonal antibody (1:400 for both) at 4°C overnight. Blots were then incubated with HRP-conjugated secondary antibodies (Amersham Pharmacia, Arlington Heights, IL) at room temperature for 1 h, and were visualized by enhanced chemiluminescence (ECL; PerkinElmer).
Cell proliferation assay
RVECs were starved in basal medium supplemented with 0.2% FBS (EBM) at 37°C overnight. After trypsinization, cells were resuspended in basal medium, and seeded at 2000 cells/well in 96-well plates. APX3330 at various concentrations was added three hours later. After 48 h incubation at 37°C, the total number of cells was assayed by using the CellTiter 96 Ò AQueous One Solution (Promega Corporation, Madison, WI). The absorbance value at 490 nm was read by a microplate reader (GENios Pro, Tecan Trading AG, Switzerland) after 1 h incubation. Experiments were performed in 5-6 wells per group each time and repeated three times.
Migration assay
Migration was performed using modified Boyden chambers containing polycarbonate membrane (Transwell, 5.0 lm pore size; Costar, Cambridge, MA) with slight modification (Cai, Rook, Jiang, Takahara, & Aiello, 2000) . Wild-type and Vldlr À/À RVECs at the same confluence were starved in basal medium overnight and then seeded at 5 Â 10 3 cells/well into Transwell plates coated with fibronectin (10 lg/ml). Basal medium supplemented with 10 ng/ml bFGF, with or without APX3330 at different concentrations were added to the lower chamber and incubated at 37°C for 16 h. Viable cells were stained with the CellTracker™ Green BODIPY Ò , fixed in 1% PFA, and counterstained with DAPI. The upper surface of the Transwell member was scraped with a cotton swab to remove un-migrating cells. Seven images of migrating cells were taken randomly from each membrane with a 10Â objective. The average number of nuclei in each image was determined. The experiment was performed in triplicate.
Real-time cell impedance analysis
Dynamic cellular biology was monitored using Real-Time Cell Analyzer single-plate (RTCA SP) Instrument, xCELLigence System (Roche Applied Science, Mannheim, Germany). The system monitors cellular events in real time measuring electrical impedance across interdigitated micro-electrode integrated on the bottom of tissue culture E-plates. The impedance measurement provides quantitative information about the biological status of the cells, including cell number, viability, and morphology. A dimensionless parameter called Cell Index (CI) is derived as a relative change in measured electrical impedance to reflect the integrated cellular status in the culture. For experiments, both wild-type and Vldlr 
Subretinal neovascularization quantification
A conjugate of isolectin IB4 from Griffonia simplicifolia (isolectin IB4 Alexa Fluor 488, Invitrogen) was used for retinal blood vessel labeling in whole flat mounts. One week after intravitreal treatment, the eyes were harvested and fixed in 1% PFA at 4°C overnight. Retinas were separated, with 4-6 radial cuts to flatten the retina. After blocking, the entire neural retina was incubated in a 1:200 diluted isolectin solution containing 3% donkey serum for 2 days at 4°C, washed with PBS, and mounted with a ProLong Gold antifade reagent (Invitrogen). Retinal images focusing on the subretinal space were photographed under an inverted fluorescence microscope at 10Â magnification (Leica DM IRB, Leica Microsystems Inc., Bannockburn, IL). A whole retinal montage was used to quantify the total number of RAP-like neovascularization with masked label.
Statistical analysis
All the statistical analyses were performed using SPSS11.0 (SPSS, Chicago, IL). Data are presented as mean ± SD. Differences were assessed using one-way or two way analysis of variance (AN-OVA) or the Student t-test. A value of p < 0.05 is considered statistically significant.
Results
APX3330 inhibits endothelial cell tube formation
Previous studies suggest that APX3330 inhibits downstream functions of HIF-1a in angiogenesis (Luo et al., 2008) . Therefore we examined the effect of APX3330 and combined effect of APX3330 and Avastin Ò , a known anti-angiogenic compound on Matrigel tube formation assay using human ECFCs. As shown in Fig. 1, APX3330 impaired the ability of these cells to form tubules.
At 10 lM, APX3330 reduced tube formation by 61%, while Avastin Ò (500 lg/ml) had little effect on tube formation. However, the combination of these two agents at these doses completely inhibited tube formation. A similar result was observed with Avastin Ò (500 lg/ml) and a lower dose of 5 lM APX3330. These data suggest that the effects of APX3330 and Avastin Ò on endothelial cell tube formation are at least additive or maybe even synergistic.
APX3330 does not induce apoptosis
APX3330 could reduce the amount of endothelial cell tube formation by inducing cell death. Therefore, TdT mediated dUTP-fluorescein nick end-labeling (TUNEL) assay was performed to quantify cell death of ECFCs in the presence and absence of APX3330. Fig. 2 shows that 24 h exposure to APX3330 does not induce apoptosis, but exposure to H 2 O 2 , a positive control, does induce apoptosis under the same condition tested. These data are consistent with the possibility that the effect of APX3330 on endothelial cell tube formation is mediated by inhibition of APE1/Ref-1 redox activity. A similar result was obtained previously (Tell et al., 2005) . Ò results in a dramatic decrease in the tube formation ability of these cells at levels much greater than either agent alone. Avastin Ò (500 lg/ml) had little effect on tube formation, 10 lM APX3330 reduced tube formation by 61%, and the combination of these two agents at these doses completely inhibited tube formation. A similar result was observed with Avastin Ò (500 lg/ml) and 5 lM APX3330.
pericytes (RPCs) (Fig. 3) . It also revealed that levels of APE1/Ref-1 protein were comparable in retinal tissues and vascular cells from wild-type and Vldlr À/À mice (Fig. 3) . No genotypic difference was noticed.
APX3330 inhibits retinal endothelial cell proliferation
To test the specific effect of APX3330 on retinal vascular cells, a serious of in vitro assays was carried out using magnetic beadspurified RVECs. We have previously showed that APX3330 inhibits proliferation of wild-type RVECs in vitro (Luo et al., 2008) , which suggests that it is likely to inhibit angiogenesis in vivo. In the present study, we have found that APX3330 inhibited the proliferation of not only wild-type but also Vldlr À/À RVECs (Fig. 4A ). This was associated with a slightly higher efficacy in Vldlr À/À RVECs (61.58 ± 7.66%) than that in wild-type RVECS (84.15 ± 9.23%). Because Vldlr À/À RVECs grow at a much faster rate (Jiang et al., 2009) , Vldlr À/À RVECs are more sensitive to APX3330 than wildtype RVECs.
APX3330 inhibits retinal endothelial cell migration
Endothelial cell migration is essential for angiogenesis. Therefore, the effect of APX3330 on migration of wild-type and Vldlr À/À RVECs was examined using a dual chamber transwell assay. Cells were seeded in the upper chamber and basic fibroblast growth factor (bFGF) (10 ng/ml) was added to the lower chamber as a chemoattractant. In the absence of APX3330, migrating Vldlr À/À RVECs (311.93 ± 4.75) were more abundant than migrating wild-type RVECs (228.28 ± 7.07) ( Fig. 4B ; p < 0.01), as reported previously (Jiang et al., 2009 
APX3330 inhibits retinal endothelial cell angiogenesis in vitro
Results presented in Fig. 1 show that APX3330 inhibits human ECFC tube formation in a dose-dependent manner. Here, we show that despite a much higher basal level of tube formation in Vldlr À/À RVECs than wild-type RVECs, addition of APX3330 was still able to inhibit such profound ability to form capillary-like structures dosedependently (Fig. 5) . The inhibitory effects of APX3330 on Vldlr À/À RVEC tube formation was already significant (p < 0.05) at 1 lM concentration (Fig. 5C ) and reached 78% reduction at 20 lM APX3330 (p < 0.01; Fig. 5B and C). The much enhanced tube formation in Vldlr À/À RVECs is consistent with our previous report (Jiang et al., 2009 ).
APX3330 reduces CI of retinal endothelial cells
A Real-Time Cell Analyzer (RTCA) was also used to monitor dynamic changes in the properties of retinal endothelial cells during prolonged exposure to APX3330. RTCA evaluates the ionic environment at an electrode/solution interface in a cell culture. RTCA output is a dimensionless parameter called Cell Index (CI), which integrates information on cell viability, number, morphology, and adhesion. RTCA assays were initiated by seeding wild-type and Vldlr À/À RVECs on an E-Plate 96 at the same density. APX3330
was added at 5, 10 and 20 lM 2 h after seeding and CI values were monitored at 30-min intervals for 72 h. As shown in Fig. 7A and B, APX3330 reduced CI values in wild-type and Vldlr À/À RVECs in a dose-and time-dependent manner. The effect was statistically significant in all three doses in both genotype RVECs (p < 0.05). Despite a significant upsurge of the growth curve, the response of Vldlr À/À RVECs to APX3330 was more dramatic than that of corresponding wild-type RVECs. This is consistent with our above findings of the more potent effects of APX3330 on Vldlr À/À RVEC proliferation (Fig. 6A) and migration than the wild-type (Fig. 6B) , while the fellow eye of the same mouse was injected with vehicle control (BSS). One week after the injection, RAP-like neovascularization were quantified in the whole mount retina stained with isolectin-FITC. In 17/20 mice (85%), the number of RAP-like neovascularization was lower in the APX3330-treated eye than in the untreated eye of the same animal (Fig. 7C) with 75% of treated eyes showing >20% reduction in RAP-like neovascularization (p = 0.000772 in paired t-test). In contrast, Avastin Ò only reduced RAP-like neovascularization in 1/7 mice (Fig. 7D) and the overall results were not significantly different. inhibiting migration (5 lM reduced by $80-90%) was lower than that for proliferation (10 lM reduced by $20-40%). Ã, p < 0.05 when compared with wild-type RVEC normal control (NC); ÃÃ, p < 0.05 when compared with Vldlr À/À RVEC NC group; #, p < 0.01 between the two NC groups. Ò (10 or 100 lg/ml) or Avastin Ò (50 lg/ml) had little or no effect to RVECs of both genotypes (p > 0.05). A significant inhibitory effect was only seen at a high dose of 200 lg/ml Avastin Ò in wild-type and Vldlr À/À RVECs (p < 0.05).
cancer-associated endothelial cells (Zou et al., 2008) . This study confirms the earlier finding that APX3330 inhibits proliferation of murine RVECs in vitro. However, an important novel finding of this study is that APX3330 has more potent growth inhibitory effects in vitro on Vldlr À/À RVECs, which are activated with respect to angiogenic function and activity, relative to wild-type RVECs (Jiang et al., 2009) This study compares and finds significant differences in the effects of APX3330 and Avastin Ò on the in vitro properties of RVECs and on RAP-like neovascularization in the eyes of Vldlr À/À mice. For example, a much higher concentration of Avastin Ò than APX3330 was required to reduce CI values of RVECs in vitro, and intravitreal Avastin Ò did not reduce RAP-like neovascularization in Vldlr À/À mice, while APX3330 strongly reduced RAP-like neovascularization after a single intravitreal injection. The weak response to Avastin Ò in this model could be due to poor cross-species immunoreactivity with murine VEGF-A (Yu et al., 2008) and it would require higher dosage. Alternatively, APE1/Ref-1 could be a more effective target than VEGF for inhibiting RVEC viability and proliferation in vitro (as measured by CI) or reducing RAP-like neovascularization in Vldlr À/À mice because APE1/Ref-1 is upstream of multiple transcription factors essential for neovascularization. Also, our data suggest that the effects of APX3330 and Avastin Ò in endothelial cell tube formation are additive or synergistic. This is not surprising as APX3330 blocks APE1/Ref-1 redox function and therefore, would block the ability of HIF-1a to bind to various downstream target promoters such as VEGF gene and other angiogenic molecules (Carmeliet et al., 1998; Gariano and Gardner, 2005) . Avastin Ò , on the other hand, is an antibody that binds to VEGF and prevents it from binding to its target receptor. While APE1/Ref-1 redox inhibition could affect multiple signaling pathways including VEGF, and Avastin Ò neutralizes VEGF molecule turned on by different mechanisms, these pathways are not necessary overlapping, rather than complementary, to each other.
In summary, this study suggests that agents such as APX3330, which inhibit APE1/Ref-1 redox activity, have potential as therapeutic agents for treating retinal neovascularization. APX3330 may be especially useful for treating neovascularization that is refractory to anti-VEGF agents. The efficacy of APX3330 on choroidal neovascularization is also being explored for treating neovascular AMD. 
